Lyra Therapeutics, Inc. (LYRA)

Lyra Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	1.68	1.56	1.36	0.29	0	0
Revenue Growth (YoY)	28.74%	14.31%	378.25%	-	-	-
Gross Profit	1.68	1.56	1.36	0.29	0	0
Selling, General & Admin	19.75	19.06	17.56	14.21	9.69	4.49
Research & Development	53.67	48.03	38.8	29.69	12.52	12.03
Other Operating Expenses	1.59	1.59	1.32	0	0	0
Operating Expenses	75.01	68.68	57.67	43.9	22.21	16.52
Operating Income	-73.33	-67.12	-56.31	-43.62	-22.21	-16.52
Other Expense / Income	-4.51	-4.5	-1.04	-0.1	-0.08	-0.21
Pretax Income	-68.82	-62.62	-55.27	-43.51	-22.13	-16.31
Income Tax	0.06	0.06	0.01	0	0	0
Net Income	-68.88	-62.68	-55.28	-43.51	-22.13	-16.31
Shares Outstanding (Basic)	64	50	30	13	9	0
Shares Outstanding (Diluted)	64	50	30	13	9	0
Shares Change	73.79%	64.72%	132.83%	51.17%	4150.62%	21.68%
EPS (Basic)	-1.20	-1.26	-1.83	-3.35	-2.59	-82.23
EPS (Diluted)	-1.20	-1.26	-1.83	-3.35	-2.59	-82.23
Free Cash Flow	-73.06	-64.35	-43.55	-29.21	-22.92	-13.97
Free Cash Flow Per Share	-1.14	-1.29	-1.44	-2.25	-2.67	-69.10
Gross Margin	100.00%	100.00%	100.00%	100.00%	-	-
Operating Margin	-4364.94%	-4308.09%	-4131.03%	-15303.51%	-	-
Profit Margin	-4099.82%	-4023.11%	-4055.61%	-15267.72%	-	-
Free Cash Flow Margin	-4348.81%	-4130.36%	-3195.08%	-10247.37%	-	-
EBITDA	-68.69	-62.34	-54.2	-42.51	-22.03	-16.28
EBITDA Margin	-4088.57%	-4001.48%	-3976.38%	-14916.49%	-	-
Depreciation & Amortization	0.13	0.28	1.07	1	0.1	0.03
EBIT	-68.82	-62.62	-55.27	-43.51	-22.13	-16.31
EBIT Margin	-4096.31%	-4019.32%	-4054.66%	-15267.72%	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).